Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
Clinical trial NCT02717884 · UNKNOWN
Trial details
- NCT number
- NCT02717884
- Sponsor
- Michael Luebbert
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-01
- Primary completion
- 2020-12-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.